Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia

BACKGROUND: While many humanized monoclonal antibodies utilize complement-dependent cytotoxicity, the complement depleting effects of these antibodies and the impact of complement replacement on treatment response are not well-described. METHODS: We conducted a phase 2 trial involving patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol
Main Authors: Tuscano, Joseph, Poh, Christina, Rosenberg, Aaron, Jonas, Brian, Abedi, Mehrdad, Barisone, Gustavo, Schwab, Emily, Lundeberg, Kathleen, Kaesberg, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: Elmer Press 2020
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7430864/
https://ncbi.nlm.nih.gov/pubmed/32855756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jh721
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados